Boswellia resin extract and propolis derived polyphenols in patients with type III chronic prostatitis/chronic pelvic pain syndrome:An Italian prospective multicenter study  

作　　者：Fabrizio Presicce Francesco Barrese Andrea Cantiani Alessio Filianoti Domenico Tuzzolo Paolo Di Palma Stefano Lauretti Stefano Brunori Marco Martini 

机构地区：[1]San Filippo Neri Hospital,Department of Urology,Rome,Italy [2]Sant’Eugenio Hospital,Department of Urology,Rome,Italy [3]Casa del Sole Clinic,Department of Urology,Formia,Italy [4]Fabrizio Spaziani Hospital,Department of Urology,Frosinone,Italy [5]Santa Caterina della Rosa Clinic,Department of Urology,Rome,Italy [6]Villa Stuart Clinic,Department of Urology,Rome,Italy

出　　处：《Asian Journal of Urology》2022年第2期139-145,共7页亚洲泌尿外科杂志（英文）

摘　　要：Objective:To assess the efficacy and safety of a treatment regimen based on rectal administration of Boswellia resin extract and propolis derived polyphenols in patients with type IIIa and type IIIb chronic prostatitis and chronic pelvic pain syndrome(CP/CPPS).Methods:Patients with type IIIa and type IIIb CP/CPPS received one rectal suppository a day for 15 days per month for 3 consecutive months.Participants were evaluated with National Institutes of Health-Chronic Prostatitis Symptom Index(NIH-CPSI),the International Prostate Symptom Scores(IPSS),International Index of Erectile Function(IIEF),four-glass test,uroflowmetry,and prostate-specific antigen assessments at baseline and at Week 4,and Week 12.Primary endpoints were improvement in pain domain of NIH-CPSI and improvement of NIH-CPSI total score.Secondary outcomes included improvement of micturition and quality of life(QoL)domains of NIH-CPSI questionnaire.Results:A total of 61 males were enrolled.No adverse events were reported.Significant improvements from baseline to Day 30 were reported for NIH-CPSI total score(mean difference:-9.2;p<0.01),NIH-CPSI pain domain(mean difference:-5.5;p<0.01),NIH-CPSI micturition domain,NIH-CPSI QoL domain,and IPSS total score(mean difference:-5.6;p<0.01).No significant changes from baseline in terms of IIEF score or maximum flow rate were observed.At final follow-up(Day 90),further significant improvements in terms of NIH-CPSI total score(mean difference:-12.2;p<0.01),NIH-CPSI pain domain(mean difference:-6.6;p<0.01),NIH-CPSI micturition domain,NIH-CPSI QoL domain,and IPSS total score were reported.Conclusion:Rectal administration of Boswellia resin extract and propolis derived polyphenols is well tolerated and delivers a significant symptomatic improvement in most patients with type IIIa and type IIIb CP/CPPS.

关 键 词：Boswellia serrata Chronic prostatitis Chronic pelvic pain syndrome PROPOLIS Treatment 

分 类 号：R697.3[医药卫生—泌尿科学]